Teladoc Health Inc. (TDOC) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Teladoc Health Inc. (TDOC) surged +26.89% to $8.73 as options desks priced 72% call premium vs. 28% put protection around the $9 max-pain magnet. Solid 41% profit margin (-17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Teladoc’s third-quarter results were met with a significant positive market reaction, reflecting investor confidence in the company’s execution despite a year-over-year revenue decline. Management cited robust progress i
Check out the companies making headlines this week:
JP Morgan analyst Lisa Gill maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $8 to $10.
Teladoc Health just ripped higher, jumping 26.9% to US$8.73 after its Q3 2026 report, a sharp rerating for a stock that had been under pressure for months. Traders are reacting to one thing above all else: profit quality
2026-10-30. The following slide deck was published by Teladoc Health, Inc.
Key TakeawaysTeladoc Health rose 11% after its third-quarter adjusted EBITDA beat guidance, rising 14% to $79. 4 million.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 24.2% in the morning session after the company reported third-quarter financial results that exceeded its adjusted EBITDA guidance and reached
Oct. 29, 2026 gap movers include NCPL, PCLA, INLF, ADT, GKOS, PRCH, CROX, CLMB, TDOC and KFIIR on the upside, plus GME.W, OPTT, LVWR and XRX on the downside.
U.S. stocks fell Thursday, led by a 9% Caterpillar drop; Porch, Teladoc and Crocs surged, while oil, gold and silver declined.
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc Health
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TDOC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TDOC. Explore sector supply chains on /butterfly.
Why TDOC Stock surged +26.89% Today — RQD Quant Desk Flash. Solid 41% profit margin (-17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.